secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-08-21T23:59:59+00:00
Accession:  0001641172-25-025104
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari raises $2.26M via unsecured notes with 20% OID; Chairman Huh exchanges prior loan
--------------------------------------------------------------------------------

- Issued notes with aggregate purchase price of $2,261,000 and principal amount of $2,826,250; maturity 12 months from closing.
- Chairman Dr. Huh purchased $1,250,000 principal note for $1,000,000, paying $162,567 cash and cancelling $837,433 Peak Bio loan.
- Extended expiration of Series A Warrants on 1,973,211 ADSs by 48 months from original expiry.
- Paid Paulson Investment Company a 5% advisory fee ($70K) on ~$1.4M gross cash proceeds.
- Notes are unsecured; proceeds used for general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000164117225025104/0001641172-25-025104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000164117225025104/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-025104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer